"Thu Apr 11, 2013 9:43am EDT
(Reuters) - Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, ...
Parkinson's disease psychosis is a debilitating disorder that develops in up to 60 percent of patients as their Parkinson's disease progresses.
Most current antipsychotic drugs cannot be used in Parkinson's disease patients as they block dopamine in the brain, which is the primary target for Parkinson's therapy, and can lead to a worsening of motor functions in such patients.
Pimavanserin works by selectively blocking certain serotonin receptors in the brain, but has no effect on dopamine..."
http://www.reuters.com/article/2013/...93A0IA20130411
John